EUVIMEDEUVIMED entdecken
VergleichsstudieÜbersichtsarbeitLeitlinieOpen Access · CC BY 4.0

Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy

Luigi Bartalena iD, Daniela Gallo iD, George J Kahaly iD, Michele Marinò iD, Maria Laura Tanda iD

European Thyroid Journal · 01.12.2025 · 14 (6)

DOI: 10.1530/etj-25-0318 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Thyroid Journal, online erschienen am 24.12.2025. Verfasst von Luigi Bartalena und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Insubria, Varese, Italy. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Practice Guidelines as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background In 2021, the European Group on Graves’ orbitopathy (EUGOGO) published clinical practice guidelines for the management of GO, and in 2022, the American and European Thyroid Associations published the ATA/ETA consensus statement on the same topic. Aims i) To highlight similarities and differences between the two documents, ii) to suggest possible amendments for future revisions. Results and conclusions The two documents show a high degree of concordance as to classification, assessment, and prevention, as well as treatment of mild GO, moderate-to-severe and inactive GO, and sight-threatening GO. The major disagreement regards treatment of moderate-to-severe and active GO. The EUGOGO guidelines, written when teprotumumab was not available outside the USA, indicate intravenous glucocorticoids (IVGC) (with/without mycophenolate) as the first-line treatment, whereas the ATA/ETA consensus statement indicates teprotumumab as the first-line treatment for virtually all phenotypes of moderate-to-severe and active GO, particularly when exophthalmos is predominant. However, also in the ATA/ETA consensus statement, IVGC are the preferred treatment when the goal is GO inactivation and resolution of inflammation, and among the preferred treatments (in combination with orbital radiotherapy) when the goals are inactivation and correction of eye dysmotility. Recent developments to be considered in future revisions of the guidelines/consensus statement include the possible use of biologicals (teprotumumab and tocilizumab) for dysthyroid optic neuropathy, treatment of longstanding inactive GO with teprotumumab, reconsideration of the cautious use of radioactive iodine in patients with moderate-to-severe and active GO concomitantly treated with IVGC (with/without orbital radiotherapy), and use of statins as an adjunct therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyPractice Guidelines as TopicHumansConsensusGlucocorticoidsAntibodies, Monoclonal, HumanizedEuropeSocieties, Medical

Stichwörter der Autor:innen

Graves’ orbitopathyconsensus statementguidelinesthyroid associated ophthalmopathythyroid eye disease

Substanzen

GlucocorticoidsAntibodies, Monoclonal, Humanizedteprotumumab

Autor:innen und Institutionen

  • School of Medicine, University of Insubria, Varese, Italy.
  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center, Mainz, Germany.
  • Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

ORCID-Profile: Luigi Bartalena, Daniela Gallo, George J Kahaly, Michele Marinò, Maria Laura Tanda

Zitieren

APA

Bartalena, L., Gallo, D., Kahaly, G. J., Marinò, M., & Tanda, M. L. (2025). Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy. European Thyroid Journal, 14(6). https://doi.org/10.1530/etj-25-0318

Vancouver

Bartalena L, Gallo D, Kahaly GJ, Marinò M, Tanda ML. Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy. European Thyroid Journal. 2025;14(6). doi:10.1530/etj-25-0318

BibTeX
@article{Bartalena2025,
  author = {Bartalena, Luigi and Gallo, Daniela and Kahaly, George J and Marinò, Michele and Tanda, Maria Laura},
  title = {Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy},
  journal = {European Thyroid Journal},
  year = {2025},
  volume = {14},
  number = {6},
  doi = {10.1530/etj-25-0318}
}
Kostenlos starten →